Does ABSI pay a dividend and is it safe?

Absci Corporation (ABSI) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / ABSI / dividends

OABI (44) NRC (67) ICLR (72) CRL (64) ⌘ Pro Terminal →

Absci Corporation (ABSI) Dividend Safety Gauge & 10-Year DRIP Compounder

$9.69 -12.94% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.45

Absci Corporation (ABSI) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $1.91B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ABSI Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ABSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Absci Corporation (NASDAQ: ABSI) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $9.69 (-12.94% 1D, market cap $1.91B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ABSI ranks #382 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ABSI compare to OABI and NRC in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), ABSI carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OABI (OmniAb Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -22.6%, cap $742.9M) and NRC (NRC Health) posts a C+ grade (67/100 RQD, P/E 44.8x, ROIC 21.0%, cap $527.1M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ABSI?

▼

Per ABSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001672688), Absci Corporation generated $336.9M in revenue (+7330.3% YoY), -$115.2M in net income, and -$94.0M in free cash flow against $216.3M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $9.45 (-2.52%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-6.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABSI)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (44/100 Composite)

🔍 WHY ABSI SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (39% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$9.10-0.3% Next Q

Q2 (-2Q)

Grade E$9.07+16.5% Next Q

Q3 (-1Q)

Grade D$10.57-8.3% Next Q

Current

Grade D$9.69-6.5% Hist 90D α

Trajectory: E (36) → D (44)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ABSI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ABSI currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.60) and Max Pain ($10.17) forces dealer call-delta covering toward $13.18.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABSI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ABSI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 44%NO 56%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ABSI)

✓Walkthrough of ABSI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ABSI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +72.42%▲ ASCENDING CHANNEL

2026-11-03O $12.10H $12.10L $9.69C $9.69VOL 4.57M

RES: $13.05SUP: $8.43SMA50: $9.60SMA200: $6.58

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ABSI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ABSI Butterfly Map → + Track ABSI →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +7330.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ABSI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ABSI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ABSI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABSI)

Health Care Rank #382 of 1015 ⚔️ OABI vs ABSI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ABSI vs. OABI, NRC, ICLR, CRL)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Absci Corporation (ABSI) ranks #382 by composite RQD confidence (44/100, grade D) and #264 by equity capitalization ($1.91B). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. ICLR currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with ABSI at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ABSI ACTIVE Absci Corporation	D	44/100	—	—	-35.0%	-12.94%	$1.91B	Benchmark Subject
OABI OmniAb Inc.	D	44/100	—	—	-22.6%	-0.39%	$742.9M	/oabi-vs-absi →
NRC NRC Health	C+	67/100	44.8x	—	21.0%	+1.80%	$527.1M	/nrc-vs-absi →
ICLR ICON plc	B	72/100	71.9x	—	3.1%	-2.94%	$16.18B	/iclr-vs-absi →
CRL Charles River Laboratories International Inc.	C	64/100	—	—	0.4%	-5.81%	$17.16B	/crl-vs-absi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001672688 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Absci Corporation (ABSI) reported GAAP revenue of $336.9M (+7330.3% vs. FY2024 revenue of $4.5M , and +5791.7% cumulative change since FY2023) , GAAP net income of -$115.2M, operating cash flow of -$92.9M, and free cash flow of -$94.0M (-29.2% YoY). On the balance sheet, ABSI closed FY2025 with $216.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$336.9M	-$115.2M	-$92.9M	-$94.0M	$216.3M	—
FY2024 (FY)	2024-12-31	$4.5M	-$103.1M	-$72.4M	-$72.8M	$213.6M	—
FY2023 (FY)	2023-12-31	$5.7M	-$110.6M	-$64.6M	-$64.6M	—	—

3. ABSI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ABSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ABSI compare to OABI and NRC in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ABSI?

Where is ABSI trading relative to its 50-day, 200-day, and 52-week technical levels?

ABSI last traded at $9.69 (-12.94% on volume of 3,813,257 shares), positioning the stock +0.94% above its 50-day simple moving average ($9.60) and +47.26% above its 200-day simple moving average ($6.58). Across its 52-week range of $2.24 to $12.55, ABSI sits at the 72.3% percentile with a 14-day RSI of 55.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($8.48 to $10.90).

Direct Sub-Reports: ABSI RQD Cockpit ABSI 12M Forecast ABSI Earnings & Move ABSI Dividends & DRIP ABSI Insiders & 13F ABSI Whale Options ABSI Profit Sankey ABSI News & Why

ROARABLE RATING BRIEF • RQD 44/100 (D) ✓ SEC XBRL & RQD VERIFIED

ABSI — Absci Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Absci Corporation (ABSI) earns a live Roarable RQD composite score of 44/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $9.69 (-12.94% 1D, market capitalization $1.91B).

Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -4.53%.
Whale 13F & Options Flow (17/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Absci Corporation (ABSI) is a NASDAQ-listed issuer..

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Absci Corporation (ABSI) reported $336.9M in annual revenue (up from $4.5M in FY2024, +7330.3% YoY) and -$115.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($5.7M revenue, -$110.6M net income) through FY2025, ABSI scaled operating cash flow to -$92.9M and free cash flow to -$94.0M, backed by $216.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D • RQD 44/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -4.53% and institutional whale pillar of 17/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 17/20, sustained execution supports upside toward the upper end of the $2.24 – $12.55 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector and industry classification are given in the profile only.

Key Question #1: Can ABSI sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Commercial Physical & Biological Resarch peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $336.9M and free cash flow of -$94.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is ABSI's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ABSI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Absci Corporation (ABSI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ABSI Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 21h ago

Absci Corporation (ABSI) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Absci (ABSI) Stock Seems Rich Against Its Book Value Backdrop

Yahoo Finance report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Absci Corporation Estimates – NASDAQ:ABSI

TradingView report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST MarketBeat • 1d ago

Absci (NASDAQ:ABSI) Stock Jumps 13.2% - Still a Buy?

MarketBeat report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Absci (NASDAQ:ABSI) Shares Down 5.5% - Here's Why

MarketBeat report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Absci Corporation (ABSI) Slides 13.47% to $10.47 as Shares Retreat Toward Key Support - Call Resistance

https://www.siam.in/ report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Absci Corporation (NASDAQ:ABSI) Stock Has Average Target Price of $13.71

MarketBeat report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Absci Corporation (NASDAQ:ABSI) Stock Rated "Moderate Buy" by Sell-Side Analysts

MarketBeat report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ABSI Bull vs. Bear Conversation Board — What's Your Call at $9.69?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ABSI 🐻 33% BEARISH CONVICTION

MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $14.14 (+27.0%)

📌 Pinned Debate

Institutional accumulation and options positioning (17 / 20 whale 13F pillar) is the rating's strongest signal.

Institutional accumulation and options positioning (17 / 20 whale 13F pillar) is the rating's strongest signal.. When you look under the hood at ABSI, Fundamental Cash Engine is 6/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (17/20) has been quietly accumulating below $12.55. My 12M target is $14.14.

RetailWhale_TX 🐂 BULL

@ForensicBear Shorting a 17/20 institutional whale-flow stock at $11.13 is dangerous when funds are rotating into Health Care.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $9.24 (-17.0%)

Spot @ $11.13

Negative ROIC of -35% and revenue falling to $0.0M in FY 2025 leave the business without cash-generating support.

Careful chasing ABSI at $11.13. Negative ROIC of -35% and revenue falling to $0.0M in FY 2025 leave the business without cash-generating support.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $9.24 on multiple compression.